Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.49 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520296 | 0.80 | MEN1 (0.53) | SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL29057258 | 0.79 | LMNA (0.51) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL9843936 | 0.79 | SMN1; SMN2 (0.77) | SMN1; SMN2KMT2AMEN1TDP1KDM4E | |
| SCHEMBL9463141 | 0.78 | SMN1; SMN2 (0.70) | SMN1; SMN2KMT2AMEN1TDP1KDM4E | |
| SCHEMBL11503802 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMEN1TDP1KDM4E | |
| SCHEMBL9463095 | 0.76 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2AMEN1TDP1KDM4E | |
| SCHEMBL28229524 | 0.76 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2AMEN1TDP1KDM4E | |
| SCHEMBL8819876 | 0.76 | KMT2A (0.61) | SMN1; SMN2KMT2AMEN1TDP1SOAT1 | |
| SCHEMBL14520298 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2ALMNA | |
| SCHEMBL190379 | 0.74 | SMN1; SMN2 (1.00) | SMN1; SMN2KMT2AMEN1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | NAFTCHI N E | 2007-04-12 | — | — | US | disclosed |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | NAFTCHI N E | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | ADRB2, ADRB1, CHRNA7 | SMN1; SMN2 150/4885KMT2A 4167/4885MEN1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.